Sotera Health Q2 net income jumps to $54M; raises FY 2026 revenue and EBITDA guidance

Sotera Health Co

Q2 net revenues +9.2% (+8.0% constant currency); net income $54M ($0.19 diluted EPS) vs $8M ($0.03) in Q2 2025.
Adjusted EBITDA +10.0% (+8.7% constant currency); Adjusted EPS $0.26, up 30% per diluted share.
Raises FY 2026 outlook: net revenue growth 5.25%-6.75%, Adjusted EBITDA growth 5.75%-7.25% on constant currency basis.
Segment constant currency growth: Sterigenics 7.0%, Nordion 16.7%, Nelson Labs 5.4%; Net leverage ratio 3.0x, liquidity ~$950M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.